Eli Lilly posts results of Phase 3 lebrikizumab trial in atopic dermatitis
Results for the Phase 3 trial of lebrikizumab with or without topical corticosteroid treatment in participants with moderate-to-severe atopic dermatitis were first posted on ClinicalTrials.gov on October 16, 2026. The completed study enrolled 301 participants and began on April 24, 2024.
Primary source
ClinicalTrials.gov results record, October 16, 2026
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Read the source: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation